A Dose of Reality with Charles Spence

Charles Spence
  • 0.0 (0)
  • CAREERS
  • UPDATED WEEKLY

Welcome to “A Dose of Reality”, the podcast where we infuse insight, laughter, and practical wisdom into the world of clinical leadership and career development. Hosted by Charles Spence, each episode offers a deep dive into the challenges and triumphs of clinical leadership, providing listeners with meaningful conversations, career insights, and a dose of inspiration to navigate their professional journeys. Whether you're a director, a C-level executive, or a clinical researcher in oncology bio-techs, this podcast is designed to empower you with the knowledge and tools needed to excel in your field. So, visit our website at www.discera-search.com, and tune in to A Dose of Reality for your prescription of career wisdom, leadership insights, and a healthy dose of laughter.  Subscribe now and join us on the journey to becoming global clinical leaders!

  1. Richard Nkulikiyinka, Chief Medical Officer at Antag Therapeutics, on Career Pivots, Trust and Why Leadership Is Never Linear

    JAN 26

    Richard Nkulikiyinka, Chief Medical Officer at Antag Therapeutics, on Career Pivots, Trust and Why Leadership Is Never Linear

    In this episode, I talked with Richard Nkulikiyinka, Chief Medical Officer at Antag Therapeutics, a Copenhagen-based biotech developing GIPR antagonists in the obesity space. Richard’s career began in the NHS, where he spent five years practicing acute medicine and intensive care—until the moment he realized he couldn’t picture himself doing the same thing for the next 30 years. That realization sparked a pivot that many physicians quietly wrestle with: leaving behind the security of the ward for the uncertainty of industry. Richard also shares what it was like to walk away from a stable VP role at Bayer during a restructuring, take an intentional career break, and use those months to reflect on what really mattered before joining Antag Therapeutics. We talk about the shift from big pharma to biotech, what he learned from leading through severe stakeholder misalignment, and why authentic communication matters more than management theory when things get messy. And yes—there’s a light-hearted detour into Berlin life, bad currywurst, and how to tell when it’s time to make serious changes in your team. Here’s What You’re In For What makes Antag Therapeutics’ culture uniqueThe hardest leadership call: deciding when the problem is you vs themThe recruitment ghosting story that every hiring manager should hear Timestamps 02:08 – Leaving the NHS: deciding what he could be “happily bored with” 04:00 – Landing his first pharma job at Bayer in drug safety 09:33 – Overview of Antag Therapeutics and GIPR vs GLP-1 13:20 – Leaving Bayer and taking a sabbatical to reset 17:08 – What it’s like to work at Antag Therapeutics—and what he looks for in candidates 18:46 – The toughest chapter: extreme stakeholder misalignment in dermatology 25:16 – Leadership lessons: firing, feedback, and the “benefit of the doubt” 29:00 – Why managers struggle to act fast—and how structure slows decisions 31:48 – Richard’s worst recruitment experience: being ghosted by agencies About Richard Richard Nkulikiyinka, is the Chief Medical Officer of Antag Therapeutics, a biotech developing GIPR antagonists within the Obesity space. A UK-trained physician, he spent five years practicing in acute medicine and intensive care within the NHS - this is also where he developed his dry sense of humour - and now he transitioned into the biopharmaceutical industry, where he has built over 17 years of experience. Prior to joining Antag, Richard served as Vice President in Clinical Development at Bayer Pharma, where he played a central role in advancing four drugs to approval. He is now ein Berliner - where we often meet for clubbing and currywurst. Connect with Richard: LinkedIn: https://www.linkedin.com/in/richard-nkulikiyinka-66336014/ Website: https://antagtx.com/ About me My name is Charles Spence and I lead Discera. After many years working in the life-science recruitment world, I decided to work for myself. Before doing recruitment, I graduated with a biomedical degree, have worked in hospitals (including translation work in Seoul, South Korea), and also spent a year working in diabetes research in Stockholm. After doing research and...

    35 min
  2. Prof. Dr. med. Markus Kosch, Head of Oncology Europe & Canada at Daiichi Sankyo on Perseverance, Patient-Centricity Beyond Slogans, and Leadership within Oncology

    JAN 19

    Prof. Dr. med. Markus Kosch, Head of Oncology Europe & Canada at Daiichi Sankyo on Perseverance, Patient-Centricity Beyond Slogans, and Leadership within Oncology

    In this episode, I talked with Prof. Dr. med. Markus Kosch, Head of Oncology Europe and Canada at Daiichi Sankyo Europe, about what it really means to lead with empathy, perseverance, and purpose in today’s biopharma world. Markus shared how losing his father to cancer at 21 shaped his commitment to oncology — and why that experience still guides his decisions decades later. After ten years in the hospital system, he faced a turning point: realizing that to help more patients, he’d have to step outside the clinic. That leap led him into industry at a time when ADCs were still an emerging idea — and he’s since built a career around transforming long-term scientific perseverance into patient impact. Markus opened up about layoffs and restructuring, learning to lead through influence rather than authority, and why “patient-centricity” has to be more than a corporate phrase. He also shared how Daiichi Sankyo invests in nurses, why he values authenticity above experience in hiring, and how he handles tough conversations — including a live role-play on what to do when an employee asks for a promotion that isn’t possible. (Find out more in the episode.) Here’s What You’re In For How to lead through influence, not authorityWhat patient-centricity really looks like inside Daiichi SankyoHow perseverance and ikigai fuel innovation Timestamps 03:00 – From hospital to industry — how his first pharma role came about 07:15 – Leading through influence instead of authority 08:10 – Guiding teams through restructuring 09:45 – How empathy and transparency define good leadership 12:10 – Patient-centric culture at Daiichi Sankyo 17:45 – Japanese lessons in ikigai 20:40 – Hiring authenticity 25:00 – Role-play: handling promotion requests and career plateaus About Markus Prof. Dr. med. Markus Kosch is Head of Oncology Europe & Canada at Daiichi Sankyo, with extensive leadership experience in oncology and global pharma. Before joining Daiichi Sankyo, he spent 16.5 years at Wyeth and Pfizer in senior roles. Trained as a physician, Markus worked for a decade treating cancer patients before moving into the pharmaceutical industry. His early personal experience with cancer — losing his father at age 21 — shaped his commitment to patient-centric innovation. Known for connecting scientific excellence with responsibility and perseverance, he focuses on advancing breakthrough oncology therapies, particularly Antibody-Drug Conjugates (ADCs). He is passionate about leadership, collaboration, and embedding patient needs at the center of every decision. Connect with Markus LinkedIn: https://www.linkedin.com/in/markus-kosch/ Daiichi Sankyo Europe: https://www.daiichi-sankyo.eu/ About me My name is Charles Spence and I lead Discera. After many years working in the life-science recruitment world, I decided to work for myself. Before doing recruitment, I graduated with a biomedical degree, have worked in hospitals (including translation work in Seoul, South Korea), and also spent a year working in diabetes research in Stockholm. After doing research and travel, a career in business and science felt the most...

    36 min
  3. Myriam Cherif, Founder of Kalyx Medical, on The Future of MSLs, Adapting to AI, and Why Curiosity Keeps You Moving Forward

    JAN 5

    Myriam Cherif, Founder of Kalyx Medical, on The Future of MSLs, Adapting to AI, and Why Curiosity Keeps You Moving Forward

    In this episode, I talked with Myriam Cherif, former Regional Medical Lead for Oncology & Emerging Markets at GSK and founder of Kalyx Medical—a consultancy focused on Medical Affairs strategy, mentoring, and AI training. I invited Myriam to join me here because she posts some of the most insightful and practical content about what life is really like as a Medical Affairs professional. She shares her journey from academia to pharma, and what it really takes to succeed in Medical Affairs without losing your sense of purpose. She opens up about the early days at Novartis, the steep transition from the lab to corporate life, and the practical lessons she learned through trial and error—most especially the KOL meeting that didn’t go as planned. She also shares the turning point that came when her role at GSK was made redundant, how that moment became the spark behind founding Kalyx Medical, and why she now helps MSLs and Medical Leads use AI with intention, and not as a gimmick. Along the way, she reflects on mentorship, resilience, and how to stand out in an industry that tests both your patience and adaptability. (Find out more in the episode.) Here’s What You’re In For Why mentorship can make or break your first MSL yearThe “so what” factor that makes a CV stand outHow AI can help MSLs read smarter, not harder Timestamps 01:15 – From PhD in molecular biology to Medical Affairs 03:07 – The reality behind the MSL role 05:30 – Starting at Novartis and feeling out of depth 06:52 – Her first KOL meeting—and what went wrong 08:08 – Why mentorship changes everything 10:17 – How long it took to land her first MSL role 15:34 – Turning objections into opportunities 22:42 – From GSK restructure to starting Kalyx Medical 25:26 – Two big mistakes companies make with AI 28:37 – How AI gives MSLs a competitive edge About Myriam Dr. Myriam Cherif is the former Regional Medical Lead – Oncology, Emerging Markets at GSK and the Founder of Kalyx Medical, a consultancy focused on medical affairs strategy and AI training. With over 14 years of experience in the pharmaceutical industry, Myriam has worked across a wide range of therapy areas, including cardiovascular, immunology, and oncology, and held leadership roles spanning the UK and emerging markets. At GSK, she led medical strategy and scientific engagement across diverse regions, ensuring compliance and excellence in oncology communication. Through Kalyx Medical, Myriam also supports biotech and pharma companies by enhancing their medical affairs capabilities and preparing teams for the evolving landscape of AI-driven drug development and engagement. Connect with Myriam LinkedIn: https://www.linkedin.com/in/myriam-cherif-phd-977a911/ Kalyx Medical: https://www.linkedin.com/company/kalyx-medical/about/ About me My name is Charles Spence and I lead Discera. After many years working in the life-science recruitment world, I decided to work for myself. Before doing recruitment, I graduated with a biomedical degree, have worked in hospitals (including translation work in Seoul, South Korea), and also spent a year working in diabetes research in...

    34 min
  4. Sven Van den Berghe, CEO of Pantera on Overpromises in Isotope Marketing, Why Culture is the Company, and Discussions in RLT Development

    11/17/2025

    Sven Van den Berghe, CEO of Pantera on Overpromises in Isotope Marketing, Why Culture is the Company, and Discussions in RLT Development

    In this episode, I talked with Sven Van den Berghe, CEO of Pantera, about his 25+ years in nuclear physics, from his early days at the Belgian Nuclear Research Center to stepping into the high-stakes world of radioisotope production. Sven speaks openly about the toughest move of his career: leaving the safety of a government research institute to run a startup where pressure, governance disputes, and fundraising could make or break the company. He explains why independent boards are essential, how culture must be defined from day one, and why money and trust suddenly matter a lot more when you’re no longer in a state-funded environment. He also shared the fine line between science and marketing in radiopharmaceuticals—the misleading claims, the half-truths about isotope supply, and how exaggeration risks turning investors and the public away from the whole field. Sven also gives a clear picture of Pantera’s mission to expand actinium-225 production, what real diversity in a team looks like, and why letting people go quickly can be the fairest option for everyone. We also spoke about Sven’s view on recruiters—the practices that cross the line and what still makes collaborations worthwhile. (Find out more in the episode.) Here’s What You’re In For Governance clashes with corporate founders in Pantera’s early yearsBuilding a leadership team that complements each other’s strengthsSven’s frustrations with recruiter behavior Timestamps 01:06 – Choosing a PhD and landing at the Belgian Nuclear Research Center 03:05 – The hardest step: leaving government research for startup life 04:49 – Governance disputes and the need for independent boards 06:32 – Lessons learned: business plans, money, and building trust in leadership teams 08:24 – Culture as the foundation of Pantera’s identity 09:02 – How hype and half-truths distort isotope marketing 10:50 – Why reliability, cost, and scale matter more than technical ability 12:13 – The danger of running down competitor isotopes 14:00 – What Pantera is building: actinium-225 supply today and long-term plans 22:22 – Hiring and why letting people go quickly can be the right call 24:08 – Sven’s frustrations with recruiter behavior About Sven Sven Van den Berghe is the CEO of PanTera, a company that aims to expand the supply of medical isotopes for cancer therapies. With a background in physics and a PhD in materials science, Sven spent more than two decades at the Belgian Nuclear Research Center (SCK CEN), where he rose through the ranks to become Institute Director. In 2021, he made the bold move from a secure government institute to leading a biotech startup—an inflection point he calls one of the hardest, but most rewarding, decisions of his career. Throughout his career, Sven has combined deep technical expertise in nuclear research with leadership in complex organizations. Today, he leads Pantera in its mission to expand the global supply of medical isotopes, drawing on his background in science, governance, and international collaboration.  Connect with Sven: LinkedIn: https://www.linkedin.com/in/svenvdberghe/ Website: https://pantera-life.com/  About me My name is Charles Spence and I lead Discera. After many years working in the life-science recruitment world, I decided to work for myself. Before doing recruitment I graduated with a biomedical degree, have worked in hospitals (including translation work in Seoul, South Korea), and also spent a year working in diabetes research in...

    27 min
  5. Catello Somma, Partner at Seroba on Working in VC, Non-Linear Biotech Careers, and advice for those seeking VC careers

    11/10/2025

    Catello Somma, Partner at Seroba on Working in VC, Non-Linear Biotech Careers, and advice for those seeking VC careers

    In this episode, I talked with Catello Somma, Partner at Seroba, to learn about his nonlinear journey from academia and biopharma into venture capital—and the realities behind building funds, backing biotech founders, and surviving industry downturns. Catello shares the turning points that shaped his career: walking away from his PhD to get closer to patients, breaking into VC after years in biotech operations, and the hard decision to leave a fund when partnership opportunities weren’t on the table. He also gives an insider’s view on what people get wrong about venture capital—the pressure of fundraising cycles, the competition for partnership seats, and why the job is far from the traditional perception of “writing checks from a couch.” And to round things off, he takes on some quick-fire questions, from his daily coffee intake to the advice he wishes he’d heard earlier in his career. (Find out more in the episode.) Here’s What You’re In For The skills biotech professionals often lack when they first enter VCThe hard truth about career progression in VC—why few ever make partnerHow the biotech funding downturn is reshaping investor behavior Timestamps 1:45 – Leaving academia, dropping a PhD, and first steps into industry 4:02 – Pros and cons of entering VC from biotech vs finance-only backgrounds 8:13 – What differentiates Seroba: flat structure, collegiality, and no egos 10:02 – How the biotech recession and closed IPO window reshaped strategies 13:11 – The biggest misconceptions about venture capital work 16:14 – The insecurity of VC careers: five-year fund cycles and job risk 17:29 – Hard lessons: breaking into VC and walking away when promotion wasn’t possible 19:35 – Quick-fire round: coffee habits, books, family life, funniest dinner with Kevin About Catello Catello Somma is a Partner at ROA Ventures, where he invests in early-stage life science companies across Europe and North America. His path into venture wasn’t straightforward: after leaving a PhD program to get closer to patients, he built his career in CROs and biotech operations, later completing an MBA to bridge the gap between science and finance.  Before joining Seroba, Catello worked on both sides of the biotech ecosystem, from building operational teams to structuring deals. Currently, he focuses on supporting founders through the toughest parts of the journey: scaling companies, navigating funding cycles, and preparing for exits. Known for his pragmatic approach and emphasis on culture, Catello brings a long-term mindset to venture—balancing the pressures of short-term market shifts with the resilience needed to build enduring biotech businesses. Connect with Catello: LinkedIn: https://www.linkedin.com/in/catellosomma/ Website: https://serobavc.com/  About me My name is Charles Spence and I lead Discera. After many years working in the life-science recruitment world, I decided to work for myself. Before doing recruitment I graduated with a biomedical degree, have worked in hospitals (including translation work in Seoul, South Korea), and also spent a year working in diabetes research in Stockholm. After doing research and travel, a career in business and science felt the most appropriate. In 2023, I decided to launch my firm - Discera Search. A firm committed to solving the biggest talent needs of early clinical stage SME biotechs on the East Coast and DACH. Connect with me: LinkedIn: a href="https://www.linkedin.com/in/charles-spence-clinical/"...

    22 min
  6. Kevin N. Heller, MD, Chief Medical Officer and Advisor to Funds and VCs, on Culture Shifts, Tough Lessons In Leadership, And The Reality Of Biotech Fundraising

    10/27/2025

    Kevin N. Heller, MD, Chief Medical Officer and Advisor to Funds and VCs, on Culture Shifts, Tough Lessons In Leadership, And The Reality Of Biotech Fundraising

    In this episode, I talked with Dr. Kevin Heller, former biotech CMO and now advisor to VCs and funds, who’s built his career at the intersection of science, leadership, and investment. Kevin started out as a pediatric hematologist–oncologist before joining BMS, where he worked on one of the first checkpoint inhibitor programs. Since then, he’s held senior roles across biotech and now works closely with companies and investors on strategy. Kevin opened up about the habits that nearly held him back early in his career, how a colleague’s honest feedback changed the way he leads, and why the quiet moments in meetings often say more about culture than the loud ones. He also shared about today’s funding climate—why raising money feels tougher than ever, what investors really look for, and why every company needs a clear plan for when things don’t go as expected. And outside of biotech, Kevin’s focus is on mentoring the next generation of scientists through the Society for Science, an organization he’s been deeply involved with for years. Here’s What You’re In For The subtle warning signs of a weak culture (and why silence is the biggest one)The kind of questions investors ask now that many companies aren’t ready forHow mentoring young scientists through the Society for Science has become Kevin’s way of giving back Timestamps 00:58 – How Kevin moved from academia into industry 06:00 – The colleague who bluntly told him to be quiet 10:20 – What Kevin has seen change in biotech fundraising over the past few years 12:34 – The advice he gives to early-stage companies heading into investor meetings 16:15 – What most outsiders don’t realize about being on the investment side 17:54 – What “culture” actually means to him, and why bad leadership kills it 20:14 – The subtle early signs of a broken culture: silence in meetings 26:48 – Kevin’s involvement with the Society for Science and mentoring future scientists About Kevin Kevin Heller is a former biotech CMO and a current advisor to funds and VCs. He serves as Investment Team Advisor at an equity fund investing in biotech. He is a Pediatric Hematologist/Oncologist, and began his career at BMS where he contributed to the development of YUR-VOY. He has held CMO roles at several biotech companies, worked on numerous early-stage programs (including at Incyte), and continues to influence the field through his advisory roles. Kevin serves as a mentor, judge, and council member of Society for Science, a nonprofit that promotes science literacy and runs major student science fairs worldwide, in his way of giving back to the mentors who guided him early in his career. For him, it’s about inspiring the next generation to see science as something they can own and shape. Connect with Kevin: LinkedIn: https://www.linkedin.com/in/kevin-n-heller-8bbb985/ Society for Science:https://www.societyforscience.org/   About me My name is Charles Spence and I lead Discera. After many years working in the life-science recruitment world, I decided to work for myself. Before doing recruitment, I graduated with a biomedical degree, have worked in hospitals (including translation work in Seoul, South Korea), and also spent a year working in diabetes research in Stockholm. After doing research and travel, a career in business and science felt the most appropriate. In 2023, I decided to launch my firm - Discera Search. A firm committed to solving the biggest talent needs of early clinical stage SME biotechs on the East

    30 min
  7. Carl Deutsch, CSO at NBE Therapeutics in Non-Linear Careers, Age Bias, and Building Great Teams

    10/13/2025

    Carl Deutsch, CSO at NBE Therapeutics in Non-Linear Careers, Age Bias, and Building Great Teams

    In this episode, I talked with Dr. Carl Deutsch, Chief Scientific Officer at NBE Therapeutics, where he shared about his path from chemistry into pharma and the lessons he’s learned along the way. Carl recalls how difficult it was to secure his first role when jobs were scarce, the pressure of multiple interview rounds, and how a non-linear career path led to both opportunities and doubts about fitting the expected mold. He discussed the differences between biotech and big pharma cultures, what it means to lead in a “cultural sandwich” role, and why accountability and agility look different depending on the environment. Carl also spoke about age bias in hiring, the importance of curiosity during interviews, and the kind of toxic hiring process that made him withdraw his application early in his career. He explained why he looks for “band members” instead of “rock stars” when building teams, how character matters more than buzzwords or tick-box credentials, and why blinded CVs often miss the real story behind a candidate. And, in a lighter moment, Carl answered a series of quick-fire questions—from his habit of quoting movies, to the kinds of conversations he avoids, to the advice he’d give to someone starting out in the industry. Here’s What You’re In For The benefits and challenges of a non-linear career pathWhy networking often matters more than a “tick-box” CVWhy blinded CVs fail to capture the real story behind a candidate Timestamps 02:20 – Scarcity and the First Job Hunt 05:10 – Non-Linear Careers and Self-Doubt 07:00 – The CV Tick-Box Trap 14:00 – Leading in a Cultural Sandwich 17:00 – What Biotech Culture Really Means 20:00 – Hiring for Accountability and Fit 23:00 – Age Bias in Pharma Hiring 30:00 – Band Members vs Rock Stars in Building a Team 32:00 – Why Blinded CVs Miss the Story 33:30 – Quick-Fire: Movie Quotes, Habits, and Career Advice About Carl Dr. Carl Deutsch, Chief Scientific Officer at NBE Therapeutics. A chemist by training, Carl earned his PhD in Dortmund, Germany, and went on to broaden his scientific horizons in the U.S. and Japan. He later added a business edge to his profile with an MBA from Mannheim Business School and ESSEC Paris. Carl played a key role in the development of Mercks first in-house antibody-drug conjugate, M9140, and also helped drive innovation as an intrapreneur, launching an award-winning project under Merck Life Science. Since 2022, he has been leading scientific strategy at NBE Therapeutics. Outside the lab, Carl has a creative side, he once took the stage as a member of an acting group and joining wild podcasts like mine. Connect with Carl: LinkedIn: https://www.linkedin.com/in/carl-deutsch-phd-mba-82ba28168/ NBE Therapeutics: https://nbe-therapeutics.com/  About me My name is Charles Spence and I lead Discera. After many years working in the life-science recruitment world, I decided to work for myself. Before doing recruitment, I graduated with a biomedical degree, have worked in hospitals (including translation work in Seoul, South Korea), and also spent a year working in diabetes research in Stockholm. After doing research and travel, a career in business and science felt the most appropriate. In 2023, I decided to launch my firm - Discera Search. A firm committed to solving the biggest talent needs of early clinical stage SME biotechs on the East Coast and DACH. Connect with me: LinkedIn: a...

    37 min
  8. Aleksandra Filipovic, Chief Medical Officer at Gallop Oncology on Perfectionism, Intuition, and the Risk of Building Unsafe Teams

    10/06/2025

    Aleksandra Filipovic, Chief Medical Officer at Gallop Oncology on Perfectionism, Intuition, and the Risk of Building Unsafe Teams

    In this episode, I talked with Dr. Aleksandra Filipovic, CMO at Gallop Oncology, a biotech developing first-in-class galectin-9 antibodies for solid tumors and blood cancers. We talked about how perfectionism shaped her early leadership, and what it took to undo it. She shared her take on hiring by “gut feel,” why that can quietly reinforce bias, and what she looks for instead. Aleksandra also opened up about her childhood—growing up with two cancer-researcher parents, skipping school to attend medical conferences—and how that path eventually led her to leave Serbia with a six-month visa and no real plan. That risk turned into a 20-year career in the UK, and a leadership journey she never could have mapped out. She once brought a pipette to school for show and tell. These days, she reads nervous systems before resumes, believes leadership is about repair—not perfection—and says her job is to “love a drug into existence.” Later this year, Aleksandra will be leading a workshop at the Society of Integrative Oncology Annual Meeting in Boston on October 27, 2025, alongside her colleagues Dr. Anna Yusim and Dr. Steve Bierman. The session, “Creating a New Kind of Intelligence in Oncology Practice” will explore neuro-somatic intelligence, noetic medicine, and mental health in oncology and biotech. CME credits and a full training curriculum will be provided. More information below. Here’s what you’re in for: Why she’s grateful her career didn’t go according to planWhy hiring based on “gut feeling” can lead to prejudice if you’re not carefulHow perfectionism quietly seeps into leadership Timestamps: 02:00 Childhood in a Cancer-Obsessed Family 06:30 Why She Left Serbia With No Job and No Plan 09:00 When Your Career Goes “Wrong”, and It’s the Best Thing That Happens 16:45 Interview Advice: “Don’t Perform—Be Honest” 21:30 What Falls Apart When Hiring Goes Wrong 23:30 The Danger of “Gut Feel” in Leadership Hiring 33:00 What It Feels Like When Your Childhood Perfectionism Takes Over at Work 36:00 How She Regulates Herself as a Leader—and Teaches Her Team To Do the Same 39:00 The Workshop: Neurosomatic Tools for Oncology Professionals About Aleksandra: Dr. Aleksandra Filipovic is the Chief Medical Officer at Gallop Oncology, where she leads oncology asset sourcing and preclinical to clinical development strategy. With a background as a clinical oncologist and a PhD in Cancer cell biology its safe to say she knows a lot about this area.   Prior to joining Gallop, Aleks still acts as the head of oncology for PureTech health and prior to this she was with BMS and also consulted for Astrazeneca. She is a practicing clinician from Imperial College London, sits on the board of a global oncology educational platform sharing progress in cancer care and hosts a podcast “Into the Body” with Dr. Alex for OncoDaily. She practices applied neuro-somatic-intelligence with cancer patients and applies these same principles in biotech leadership.  Connect with Aleksandra: Linkedin: https://www.linkedin.com/in/aleksandra-filipovic-md-ph-d-0b63441b/  From Our Guest — Upcoming Workshop for Oncology Professionals Are you in the oncology field, feeling the weight of burnout and seeking ways to enhance your patient care within the limited time you have in clinic? Reconnect to the core of your work with our upcoming workshop. Join Dr. Anna Yusim, @SteveBierman from Andrew Weil Center for Integrative Medicine, and myself for an impactful session in Boston on October 27th from 8-9:45AM. This workshop is a part of the Society for Integrative Oncology...

    35 min
See All (64)

Trailer

About

Welcome to “A Dose of Reality”, the podcast where we infuse insight, laughter, and practical wisdom into the world of clinical leadership and career development. Hosted by Charles Spence, each episode offers a deep dive into the challenges and triumphs of clinical leadership, providing listeners with meaningful conversations, career insights, and a dose of inspiration to navigate their professional journeys. Whether you're a director, a C-level executive, or a clinical researcher in oncology bio-techs, this podcast is designed to empower you with the knowledge and tools needed to excel in your field. So, visit our website at www.discera-search.com, and tune in to A Dose of Reality for your prescription of career wisdom, leadership insights, and a healthy dose of laughter.  Subscribe now and join us on the journey to becoming global clinical leaders!

Information